Table 4.
Exosome-based clinical applications for cancer treatment from clinical trials.com and references
| Cancer | Phase | Start year | Source of exosome | Therapeutic cargo | Status | Sponsor | Clinical trial number/Reference |
|---|---|---|---|---|---|---|---|
| Metastatic pancreas cancer with KrasG12D mutation | I | 2018 | Mesenchymal stromal cells | krasG12D siRNA | Ongoing | M.D. Anderson Cancer Center, Houston, Texas, United States | NCT03608631 |
| Non-small cell lung cancer | II | 2010 | Dendritic cells | Metronomic cyclophosphamide | Completed | Institute Gustave Roussy, Villejuif, France | NCT01159288 |
| Colon cancer | I | 2011 | Plant | Curcumin | Recruiting | University of Louisville Hospital, Louisville, Kentucky, United States | NCT01294072 |
| Head and neck cancer | I | 2012 | Grape | Lortab, fentanyl patch, mouthwash | Active, not recruiting | James Graham Brown Cancer Center, Louisville, Kentucky, United States | NCT01668849 |
| Malignant glioma of brain | I | 2012 | Tumor cells | IGF-1R antisense oligodeoxynucleotide | Completed | Thomas Jefferson University Hospital; Jefferson Hospital for Neurosciences, Philadelphia, Pennsylvania, United States | NCT01550523 |
| Malignant glioma neoplasms | I | 2015 | Tumor cells | IGF-1R antisense oligodeoxynucleotide | Completed | Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States | NCT02507583 |
| Metastatic melanoma | I | 2000 | Autologous dendritic cell | Pulsed with MAGE 3 tumor peptides | Completed | Institute Curie, Paris, France | [189] |
| Non-small cell lung cancer | I | 2000 | Autologous dendritic cell | Pulsed with MAGE-A3, -A4, -A10, and MAGE-3DPO4 tumor peptides | Completed | Duke University Medical Center, Durham, NC, USA | [190] |
| Colorectal cancer | I | 2006 | Autologous ascites | The granulocyte–macrophage colony-stimulating factor | Completed | The Fourth Hospital Affiliated to Guangxi Medical University, Liuzhou, China | [191] |